Is paclitaxel associated with higher mortality? The DCB in periphery conundrum: my perspective

About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.

After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.

Therefore, we are presenting our point of view regarding the topic, as expressed in some published editorials.

Today we are presenting the last one:

“Mortality Increase and Paclitaxil-Coated Device Use” December 2019

Is paclitaxel associated with higher mortality? The DCB in periphery conundrum: my perspective

About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.

After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.

Therefore, we are presenting our point of view regarding the topic, as expressed in some published editorials.

Today we are presenting the following one:

“The hypothesis of an increased mortality following paclitaxel coated device use in peripheral vascular interventions (and the emerging era of meta-analysis based evidence)” 22.10.19

Is paclitaxel associated with higher mortality? The DCB in periphery conundrum: my perspective

About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.

After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.

Therefore,  we are presenting our point of view regarding the topic, as expressed in some published editorials.

Today we are presenting the second one:

Paclitaxel Drug-Coated Balloons in Peripheral Artery Disease: Who’s Trying to Shoot the Football Star?28.06.19

Is paclitaxel associated with higher mortality? The DCB in periphery conundrum: my perspective

About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.

After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.

Therefore, during the next weeks we are presenting our point of view regarding the topic, as expressed in some published editorials.

Today we are presenting the first one:

Use of Paclitaxel-Eluting Technologies in the Femoropopliteal Segment Under Scrutiny Over Possible Link to Late All-Cause Mortality: Time to Panic or an Opportunity to Resurge?” 26.02.19